{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:35Z","timestamp":1787019635329,"version":"build-2736575974"},"reference-count":42,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,13]]},"abstract":"<jats:p>In amyloid light chain (AL) amyloidosis, amyloid fibrils derived from immunoglobulin light chain are deposited in many organs, interfering with their function. The etiology of AL amyloidosis is poorly understood. Summary data from genome-wide association studies (GWASs) of multiple phenotypes can be exploited by Mendelian randomization (MR) methodology to search for factors influencing AL amyloidosis risk. We performed a 2-sample MR analyzing 72 phenotypes, proxied by 3461 genetic variants, and summary genetic data from a GWAS of 1129 AL amyloidosis cases and 7589 controls. Associations with a Bonferroni-defined significance level were observed for genetically predicted increased monocyte counts (P = 3.8 \u00d7 10\u22124) and the tumor necrosis factor receptor superfamily member 17 (TNFRSF17) gene (P = 3.4 \u00d7 10\u22125). Two other associations with the TNFRSF (members 6 and 19L) reached a nominal significance level. The association between genetically predicted decreased fibrinogen levels may be related to roles of fibrinogen other than blood clotting. be related to its nonhemostatic role. It is plausible that a causal relationship with monocyte concentration could be explained by selection of a light chain\u2013producing clone during progression of monoclonal gammopathy of unknown significance toward AL amyloidosis. Because TNFRSF proteins have key functions in lymphocyte biology, it is entirely plausible that they offer a potential link to AL amyloidosis pathophysiology. Our study provides insight into AL amyloidosis etiology, suggesting high circulating levels of monocytes and TNFRSF proteins as risk factors.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004423","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T11:35:22Z","timestamp":1625571322000},"page":"2725-2731","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Search for AL amyloidosis risk factors using Mendelian randomization"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7221-1358","authenticated-orcid":false,"given":"Charlie N.","family":"Saunders","sequence":"first","affiliation":[{"name":"Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhayan","family":"Chattopadhyay","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Lund University, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Huhn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Weinhold","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany;"},{"name":"Department of Biomedicine, University of Basel, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8770-2464","authenticated-orcid":false,"given":"Markus M.","family":"N\u00f6then","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, University of Bonn, School of Medicine and University Hospital Bonn, Bonn, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Heinz","family":"J\u00f6ckel","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics, Biometry, and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f6rge","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Institute for Medical Informatics, Biometry, and Epidemiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Landi","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Pisa, Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany;"},{"name":"National Centre of Tumor Diseases, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2268-9422","authenticated-orcid":false,"given":"Paolo","family":"Milani","sequence":"additional","affiliation":[{"name":"Amyloidosis Research and Treatment Center, Foundation \u201cIstituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo\u201d and Department of Molecular Medicine, University of Pavia, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[{"name":"Amyloidosis Research and Treatment Center, Foundation \u201cIstituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo\u201d and Department of Molecular Medicine, University of Pavia, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Rowcieno","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Hawkins","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1917-6746","authenticated-orcid":false,"given":"Ute","family":"Hegenbart","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-5138","authenticated-orcid":false,"given":"Giovanni","family":"Palladini","sequence":"additional","affiliation":[{"name":"Amyloidosis Research and Treatment Center, Foundation \u201cIstituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo\u201d and Department of Molecular Medicine, University of Pavia, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Wechalekar","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London Medical School, Royal Free Hospital Campus, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Sch\u00f6nland","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9857-4728","authenticated-orcid":false,"given":"Asta","family":"F\u00f6rsti","sequence":"additional","affiliation":[{"name":"Hopp Children\u2019s Cancer Center, Heidelberg, Germany;"},{"name":"Division of Pediatric Neuro-oncology, German Cancer Research Center, German Cancer Consortium, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Houlston","sequence":"additional","affiliation":[{"name":"Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2769-3316","authenticated-orcid":false,"given":"Kari","family":"Hemminki","sequence":"additional","affiliation":[{"name":"Biomedical Center, Faculty of Medicine and Biomedical Center in Pilsen, Charles University in Prague, Pilsen, Czech Republic; and"},{"name":"Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"issue":"14","key":"2021070615351413300_B1","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","article-title":"Amyloidosis: pathogenesis and new therapeutic options","volume":"29","author":"Merlini","year":"2011","journal-title":"J Clin Oncol."},{"key":"2021070615351413300_B2","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.5045\/br.2020.S009","article-title":"AL amyloidosis: advances in diagnosis and management","volume":"55","author":"Koh","year":"2020","journal-title":"Blood Res."},{"issue":"1","key":"2021070615351413300_B3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers."},{"issue":"22","key":"2021070615351413300_B4","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.2174\/1568026611212220007","article-title":"Amyloid formation in light chain amyloidosis","volume":"12","author":"Ramirez-Alvarado","year":"2012","journal-title":"Curr Top Med Chem."},{"issue":"1","key":"2021070615351413300_B5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev-biochem-072611-130030","article-title":"Systemic amyloidoses","volume":"82","author":"Blancas-Mej\u00eda","year":"2013","journal-title":"Annu Rev Biochem."},{"issue":"76","key":"2021070615351413300_B6","doi-asserted-by":"crossref","first-page":"10664","DOI":"10.1039\/C8CC04396E","article-title":"Immunoglobulin light chain amyloid aggregation","volume":"54","author":"Blancas-Mejia","year":"2018","journal-title":"Chem Commun (Camb)."},{"issue":"3","key":"2021070615351413300_B7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s12640-018-9895-1","article-title":"Clearance of amyloid beta and tau in Alzheimer\u2019s Disease: from mechanisms to therapy","volume":"34","author":"Xin","year":"2018","journal-title":"Neurotox Res."},{"key":"2021070615351413300_B8","first-page":"181","article-title":"Immunoglobin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Gertz","year":"2011","journal-title":"Am J Hematol."},{"issue":"6","key":"2021070615351413300_B9","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia."},{"issue":"6","key":"2021070615351413300_B10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med."},{"issue":"4","key":"2021070615351413300_B11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.beha.2007.08.001","article-title":"Epidemiology of the plasma-cell disorders","volume":"20","author":"Kyle","year":"2007","journal-title":"Best Pract Res Clin Haematol."},{"issue":"1","key":"2021070615351413300_B12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00277-010-1028-8","article-title":"Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature","volume":"90","author":"Siragusa","year":"2011","journal-title":"Ann Hematol."},{"issue":"4","key":"2021070615351413300_B13","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41375-019-0619-1","article-title":"Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance","volume":"34","author":"Chattopadhyay","year":"2020","journal-title":"Leukemia."},{"issue":"8","key":"2021070615351413300_B14","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/leu.2016.387","article-title":"Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma","volume":"31","author":"da Silva Filho","year":"2017","journal-title":"Leukemia."},{"issue":"1","key":"2021070615351413300_B15","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1186\/1471-2458-12-974","article-title":"Incidence and survival in non-hereditary amyloidosis in Sweden","volume":"12","author":"Hemminki","year":"2012","journal-title":"BMC Public Health."},{"issue":"4","key":"2021070615351413300_B16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in England: an epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br J Haematol."},{"issue":"2","key":"2021070615351413300_B17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41416-020-01083-1","article-title":"Searching for causal relationships of glioma: a phenome-wide Mendelian randomisation study","volume":"124","author":"Saunders","year":"2021","journal-title":"Br J Cancer."},{"issue":"10","key":"2021070615351413300_B18","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/bloodadvances.2020001502","article-title":"Search for multiple myeloma risk factors using Mendelian randomization","volume":"4","author":"Went","year":"2020","journal-title":"Blood Adv."},{"issue":"9","key":"2021070615351413300_B19","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajh.24433","article-title":"Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment","volume":"91","author":"Gertz","year":"2016","journal-title":"Am J Hematol."},{"issue":"10","key":"2021070615351413300_B20","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.3324\/haematol.2017.171108","article-title":"Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts","volume":"102","author":"Meziane","year":"2017","journal-title":"Haematologica."},{"issue":"5","key":"2021070615351413300_B21","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/1055-9965.EPI-19-0803","article-title":"Lipid trait variants and the risk of non-Hodgkin lymphoma subtypes: a Mendelian randomization study","volume":"29","author":"Kleinstern","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"2021070615351413300_B22","doi-asserted-by":"crossref","first-page":"e34408","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome","volume":"7","author":"Hemani","year":"2018","journal-title":"eLife."},{"issue":"3","key":"2021070615351413300_B23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med."},{"issue":"3","key":"2021070615351413300_B24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","article-title":"Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden","volume":"123","author":"Turesson","year":"2014","journal-title":"Blood."},{"issue":"1","key":"2021070615351413300_B25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/leu.2016.140","article-title":"Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival","volume":"31","author":"Muchtar","year":"2017","journal-title":"Leukemia."},{"issue":"1","key":"2021070615351413300_B26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2019.06.021","article-title":"Pas de deux: control of anti-tumor immunity by cancer-associated inflammation","volume":"51","author":"Shalapour","year":"2019","journal-title":"Immunity."},{"issue":"12","key":"2021070615351413300_B27","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/cells8121526","article-title":"Tumor-associated macrophages in hematologic malignancies: new insights and targeted therapies","volume":"8","author":"Petty","year":"2019","journal-title":"Cells."},{"issue":"9","key":"2021070615351413300_B28","first-page":"806","article-title":"Multiple myeloma and the immune microenvironment","volume":"17","author":"Kawano","year":"2017","journal-title":"Curr Cancer Drug Targets."},{"issue":"1","key":"2021070615351413300_B29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1152\/physrev.00045.2017","article-title":"The TNF family of ligands and receptors: communication modules in the immune system and beyond","volume":"99","author":"Dostert","year":"2019","journal-title":"Physiol Rev."},{"issue":"4","key":"2021070615351413300_B30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia."},{"issue":"2","key":"2021070615351413300_B31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"de Larrea","year":"2020","journal-title":"Blood Cancer Discov."},{"issue":"7","key":"2021070615351413300_B32","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jcyt.2017.03.077","article-title":"Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis","volume":"19","author":"Rosenzweig","year":"2017","journal-title":"Cytotherapy."},{"key":"2021070615351413300_B33","doi-asserted-by":"crossref","first-page":"624573","DOI":"10.3389\/fonc.2020.624573","article-title":"Beyond Andromeda: improving therapy for light chain amyloidosis","volume":"10","author":"Kaufman","year":"2021","journal-title":"Front Oncol."},{"issue":"7","key":"2021070615351413300_B34","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.molmed.2018.05.004","article-title":"Beyond cell death: new functions for TNF family cytokines in autoimmunity and tumor immunotherapy","volume":"24","author":"Yi","year":"2018","journal-title":"Trends Mol Med."},{"issue":"6","key":"2021070615351413300_B35","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood-2004-12-4831","article-title":"Fas signal links innate and adaptive immunity by promoting dendritic-cell secretion of CC and CXC chemokines","volume":"106","author":"Guo","year":"2005","journal-title":"Blood."},{"issue":"10","key":"2021070615351413300_B36","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/eji.201847633","article-title":"RELT negatively regulates the early phase of the T-cell response in mice","volume":"48","author":"Choi","year":"2018","journal-title":"Eur J Immunol."},{"issue":"1","key":"2021070615351413300_B37","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1038\/s41467-018-04989-w","article-title":"Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma","volume":"9","author":"Went","year":"2018","journal-title":"Nat Commun."},{"issue":"6","key":"2021070615351413300_B38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2018-07-818211","article-title":"The multifaceted role of fibrinogen in tissue injury and inflammation","volume":"133","author":"Luyendyk","year":"2019","journal-title":"Blood."},{"issue":"10","key":"2021070615351413300_B39","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/ajh.25576","article-title":"Prevalence and prognostic value of D-dimer elevation in patients with AL amyloidosis","volume":"94","author":"Pudusseri","year":"2019","journal-title":"Am J Hematol."},{"issue":"10","key":"2021070615351413300_B40","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.acvd.2013.06.051","article-title":"Cardiac amyloidosis: updates in diagnosis and management","volume":"106","author":"Mohty","year":"2013","journal-title":"Arch Cardiovasc Dis."},{"issue":"5","key":"2021070615351413300_B41","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2141.2010.08288.x","article-title":"High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients","volume":"150","author":"Kastritis","year":"2010","journal-title":"Br J Haematol."},{"issue":"11","key":"2021070615351413300_B42","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.ejca.2006.02.017","article-title":"Angiogenesis in multiple myeloma","volume":"42","author":"Jakob","year":"2006","journal-title":"Eur J Cancer."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/13\/2725\/1811702\/advancesadv2021004423.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/13\/2725\/1811702\/advancesadv2021004423.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T11:35:52Z","timestamp":1625571352000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/13\/2725\/476268\/Search-for-AL-amyloidosis-risk-factors-using"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":42,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,7,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004423","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]}}}